United Therapeutics annual debt-to-equity ratio
2009
2010
2013
2014
2015
2019
2021
2022
2023
2024
United Therapeutics Debt-to-Equity Ratio Growth & History (UTHR)
United Therapeutics's debt-to-equity ratio was 0.05 for fiscal 2024.
View full United Therapeutics company overviewUnited Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.05 | −0.07 | −60.20% |
| 2023 | 2023-12-31 | 0.12 | −0.05 | −29.87% |
| 2022 | 2022-12-31 | 0.17 | −0.04 | −17.47% |
| 2021 | 2021-12-31 | 0.20 | — | — |
| 2019 | 2019-12-31 | 0.00 | — | — |
| 2015 | 2015-12-31 | 0.00 | −0.10 | −96.66% |
| 2014 | 2014-12-31 | 0.10 | −0.07 | −40.64% |
| 2013 | 2013-12-31 | 0.17 | — | — |
| 2010 | 2010-12-31 | 0.27 | −0.07 | −20.86% |
| 2009 | 2009-12-31 | 0.34 | — | — |
United Therapeutics quarterly debt-to-equity ratio
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q1.19
Q2.19
Q3.19
Q4.19
Q3.22
Q4.24
Q1.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | 0.03 | — | — |
| Q4 2024 | 2024-12-31 | 0.05 | — | — |
| Q3 2022 | 2022-09-30 | 0.00 | — | — |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
| Q3 2019 | 2019-09-30 | 0.00 | — | — |
| Q2 2019 | 2019-06-30 | 0.00 | — | — |
| Q1 2019 | 2019-03-31 | 0.00 | — | — |
| Q2 2016 | 2016-06-30 | 0.00 | −0.03 | −98.39% |
| Q1 2016 | 2016-03-31 | 0.00 | −0.10 | −97.01% |
| Q4 2015 | 2015-12-31 | 0.00 | −0.10 | −96.66% |
| Q3 2015 | 2015-09-30 | 0.02 | −0.17 | −89.25% |
| Q2 2015 | 2015-06-30 | 0.03 | −0.16 | −83.57% |
| Q1 2015 | 2015-03-31 | 0.11 | −0.06 | −36.52% |
| Q4 2014 | 2014-12-31 | 0.10 | −0.07 | −40.64% |
| Q3 2014 | 2014-09-30 | 0.19 | 0.02 | +12.64% |
| Q2 2014 | 2014-06-30 | 0.19 | 0.01 | +4.73% |
| Q1 2014 | 2014-03-31 | 0.17 | — | — |
| Q4 2013 | 2013-12-31 | 0.17 | — | — |
| Q3 2013 | 2013-09-30 | 0.17 | — | — |
| Q2 2013 | 2013-06-30 | 0.18 | — | — |
| Q3 2011 | 2011-09-30 | 0.23 | −0.05 | −16.96% |
| Q2 2011 | 2011-06-30 | 0.24 | −0.05 | −16.38% |
| Q1 2011 | 2011-03-31 | 0.26 | — | — |
| Q4 2010 | 2010-12-31 | 0.27 | −0.07 | −20.86% |
| Q3 2010 | 2010-09-30 | 0.28 | — | — |
| Q2 2010 | 2010-06-30 | 0.29 | — | — |
| Q4 2009 | 2009-12-31 | 0.34 | — | — |
United Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, United Therapeutics's debt-to-equity ratio increased from 0.00 to 0.05, a change of 0.04. The latest reported quarter, Q1 2025, shows 0.03.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review United Therapeutics source filings ↗